Literature DB >> 19902390

Pharmacogenetics and pharmacoepigenetics of gemcitabine.

M Candelaria1, E de la Cruz-Hernández, E Pérez-Cárdenas, C Trejo-Becerril, O Gutiérrez-Hernández, A Dueñas-González.   

Abstract

Gemcitabine (2',2'-difluoro 2'deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug's therapeutic use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual variation in therapeutic outcome exhibited by gemcitabine.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19902390     DOI： 10.1007/s12032-009-9349-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  98 in total

Review 1.  The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.

Authors:  Marilyn L Clarke; John R Mackey; Stephen A Baldwin; James D Young; Carol E Cass
Journal:  Cancer Treat Res       Date:  2002

2.  Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.

Authors:  K Smid; A M Bergman; P P Eijk; G Veerman; V W T Ruiz van Haperen; P van den Ijssel; B Ylstra; G J Peters
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2006       Impact factor: 1.381

3.  Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein.

Authors:  W P Gati; A R Paterson; L M Larratt; A R Turner; A R Belch
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

4.  Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.

Authors:  John R Mackey; Lori L Jennings; Marilyn L Clarke; Cheryl L Santos; Laith Dabbagh; Michaela Vsianska; Sheryl L Koski; Robert W Coupland; Stephen A Baldwin; James D Young; Carol E Cass
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

5.  Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.

Authors:  M P Lostao; J F Mata; I M Larrayoz; S M Inzillo; F J Casado; M Pastor-Anglada
Journal:  FEBS Lett       Date:  2000-09-15       Impact factor: 4.124

6.  Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).

Authors:  I Badagnani; W Chan; R A Castro; C M Brett; C C Huang; D Stryke; M Kawamoto; S J Johns; T E Ferrin; E J Carlson; E G Burchard; K M Giacomini
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 7.  Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.

Authors:  Ying Huang
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

8.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Authors:  Elisa Giovannetti; Mario Del Tacca; Valentina Mey; Niccola Funel; Sara Nannizzi; Sergio Ricci; Cinzia Orlandini; Ugo Boggi; Daniela Campani; Marco Del Chiaro; Mauro Iannopollo; Generoso Bevilacqua; Franco Mosca; Romano Danesi
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Authors:  V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

10.  Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.

Authors:  Ioannis Boukovinas; Chara Papadaki; Pedro Mendez; Miquel Taron; Dimitris Mavroudis; Anastasios Koutsopoulos; Maria Sanchez-Ronco; Jose Javier Sanchez; Maria Trypaki; Eustathios Staphopoulos; Vassilis Georgoulias; Rafael Rosell; John Souglakos
Journal:  PLoS One       Date:  2008-11-11       Impact factor: 3.240
View more
  7 in total

1.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

Review 2.  The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.

Authors:  Y He; J R Chevillet; G Liu; T K Kim; K Wang
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

3.  A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.

Authors:  Christina H Wei; Tristan R Gorgan; David A Elashoff; O Joe Hines; James J Farrell; Timothy R Donahue
Journal:  Pancreas       Date:  2013-11       Impact factor: 3.327

4.  DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

Authors:  Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

5.  Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

Authors:  Gonzalo Lopez; Danielle Braggio; Abeba Zewdu; Lucia Casadei; Kara Batte; Hemant Kumar Bid; David Koller; Peter Yu; Obiajulu Hans Iwenofu; Anne Strohecker; Edwin Choy; Dina Lev; Raphael Pollock
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

6.  Novel method for DNA methylation analysis using high-performance liquid chromatography and its clinical application.

Authors:  Takuya Yotani; Yuriko Yamada; Eri Arai; Ying Tian; Masahiro Gotoh; Motokiyo Komiyama; Hiroyuki Fujimoto; Michiie Sakamoto; Yae Kanai
Journal:  Cancer Sci       Date:  2018-04-17       Impact factor: 6.716

7.  The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.

Authors:  Constantia Pantelidou; Gioia Cherubini; Nick R Lemoine; Gunnel Halldén
Journal:  Oncotarget       Date:  2016-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.